首站-论文投稿智能助手
典型文献
Neutralization of five SARS-CoV-2 variants of concern by convalescent and BBIBP-CorV vaccinee serum
文献摘要:
The prevalence of SARS-CoV-2 variants of concern(VOCs)is still escalating throughout the world.However,the level of neutralization of the inactivated viral vaccine recipients'sera and convalescent sera against all VOCs,including B.1.1.7(Alpha),B.1.351(Beta),P.1(Gamma),B.1.617.2(Delta),and B.1.1.529(Omicron)remains to be lack of comparative analysis.Therefore,we constructed pseudoviruses of five VOCs using a lentiviral-based system and analyzed their viral infectivity and neutralization resistance to convalescent and BBIBP-CorV vaccinee serum at different times.Our results show that,compared with the wild-type strain(WT),five VOC pseudoviruses showed higher infection,of which B.1.617.2 and B.1.1.529 variant pseudoviruses exhibited higher infection rates than wild-type or other VOC strains,respectively.Sera from 10 vaccinated individuals at the 1,3 and 5-month post second dose or from 10 convalescent at 14 and 200 days after discharge retained neutralizing activity against all strains but exhibited decreased neutralization activity significantly against the five VOC variant pseudoviruses over time compared to WT.Notably,100%(30/30)of the vaccinee serum samples showed more than a 2.5-fold reduction in neutralizing activity against B.1.1.529,and 90%(18/20)of the convalescent serum samples showed more than 2.5-fold reduction in neutralization against B.1.1.529.These findings demonstrate the reduced protection against the VOCs in vaccinated and convalescent individuals over time,indicating that it is necessary to have a booster shot and develop new vaccines capable of eliciting broad neutralization antibodies.
文献关键词:
作者姓名:
Yuqi Zhu;Xinyi Yang;Jingna Xun;Jun Liu;Qing Wen;Yixiao Lin;Xiaoting Shen;Jun Chen;Songhua Yuan;Xiaying Zhao;Jing Wang;Hanyu Pan;Jinlong Yang;Zhiming Liang;Yue Liang;Qinru Lin;Huitong Liang;Min Li;Jianping Liu;Yinzhong Shen;Xiaoyan Zhang;Pengfei Wang;Daru Lu;Chunhua Yin;Jianqing Xu;Shibo Jiang;Hongzhou Lu;Huanzhang Zhu
作者机构:
State Key Laboratory of Genetic Engineering and Engineering Research Center of Gene Technology,Ministry of Education,Institute of Genetics,School of Life Sciences,Fudan University,Shanghai,200438,China;Scientific Research Center,Shanghai Public Health Clinical Center,Fudan University,Shanghai,201508,China;Fubio(Suzhou)Biomedical Technology Co.,Ltd,Suzou,215300,China;Department of Infectious Diseases and Immunology,Shanghai Public Health Clinical Center,Fudan University,Shanghai,201508,China;Key Laboratory of Medical Molecular Virology(MOE/NHC/CAMS),School of Basic Medical Sciences,Fudan University,Shanghai,200032,China;Department of Infectious Diseases and Nursing Research Institution,National Clinical Research Center for Infectious Diseases,The Third People's Hospital of Shenzhen,Shenzhen,518112,China
文献出处:
引用格式:
[1]Yuqi Zhu;Xinyi Yang;Jingna Xun;Jun Liu;Qing Wen;Yixiao Lin;Xiaoting Shen;Jun Chen;Songhua Yuan;Xiaying Zhao;Jing Wang;Hanyu Pan;Jinlong Yang;Zhiming Liang;Yue Liang;Qinru Lin;Huitong Liang;Min Li;Jianping Liu;Yinzhong Shen;Xiaoyan Zhang;Pengfei Wang;Daru Lu;Chunhua Yin;Jianqing Xu;Shibo Jiang;Hongzhou Lu;Huanzhang Zhu-.Neutralization of five SARS-CoV-2 variants of concern by convalescent and BBIBP-CorV vaccinee serum)[J].中国病毒学,2022(06):831-841
A类:
vaccinee,pseudoviruses,Sera
B类:
Neutralization,five,SARS,CoV,variants,concern,by,convalescent,BBIBP,CorV,serum,prevalence,VOCs,still,escalating,throughout,world,However,level,neutralization,inactivated,recipients,sera,against,all,including,Alpha,Beta,Gamma,Delta,Omicron,remains,be,lack,comparative,analysis,Therefore,constructed,using,lentiviral,system,analyzed,their,infectivity,resistance,different,times,Our,results,that,compared,wild,type,WT,showed,higher,infection,which,exhibited,rates,than,other,strains,respectively,from,vaccinated,individuals,month,post,second,dose,days,after,discharge,retained,neutralizing,activity,but,decreased,significantly,over,Notably,samples,more,fold,reduction,These,findings,demonstrate,reduced,protection,indicating,necessary,have,booster,shot,develop,new,vaccines,capable,eliciting,broad,antibodies
AB值:
0.483177
相似文献
Urinary bladder cancer as a late sequela of traumatic spinal cord injury
Ralf Böthig;Christian Tiburtius;Wolfgang Schöps;Michael Zellner;Oliver Balzer;Birgitt Kowald;Sven Hirschfeld;Roland Thietje;Aki Pietsch;Ines Kurze;Martin Forchert;Thura Kadhum;Klaus Golka-Department of Neuro-Urology,Centre for Spinal Cord Injuries,BG Klinikum Hamburg,21033 Hamburg,Germany;Urological Practice,53757 Sankt Augustin,Germany;Department of Urology and Neuro-Urology,Johannesbad Fachklinik,94072 Bad Füssing,Germany;Biomechanical Laboratory,Centre for Spinal Cord Injuries,BG Klinikum Hamburg,21033 Hamburg,Germany;Centre for Spinal Cord Injuries,BG Klinikum Hamburg,21033 Hamburg,Germany;Department of Sports and Rehabilitation Medicine,BG Klinikum Hamburg,21033 Hamburg,Germany;Department of Paraplegiology and Neuro-Urology,Centre for Spinal Cord Injuries,Zentralklinik Bad Berka,99437 Bad Berka,Germany;Staff Position Accident Insurance Law,Statutory Accident Insurance for Wood and Metal(BGHM),33602 Bielefeld,Germany;Department of Psychosomatic Rehabilitation,Mittelrheinklinik Fachklinik,56154 Boppard-Bad Salzig,Germany;Clinical Occupational Medicine,Leibniz Research Centre for Working Environment and Human Factors at TU Dortmund(IfADo),44139 Dortmund,Germany
A novel STING agonist-adjuvanted pan-sarbecovirus vaccine elicits potent and durable neutralizing antibody and T cell responses in mice,rabbits and NHPs
Zezhong Liu;Jie Zhou;Wei Xu;Wei Deng;Yanqun Wang;Meiyu Wang;Qian Wang;Ming Hsieh;Jingming Dong;Xinling Wang;Weijin Huangei;Lixiao Xing;Miaoling He;Chunlin Tao;Youhua Xie;Yilong Zhang;Youchun Wang;Jincun Zhao;Zhenghong Yuan;Chuan Qin;Shibo Jiang;Lu Lu-Key Laboratory of Medical Molecular Virology(MOE/NHC/CAMS),School of Basic Medical Sciences;Shanghai Institute of Infectious Disease and Blosecurity;Biosafety Level 3 Laboratory,Shanghai Medical College,Shanghai Frontiers Science Center of Pathogenic Microbes and Infection,Fudan University,Shanghai,China;Key Laboratory of Human Disease Comparative Medicine,National Health Commission of the People's Republic of China;Beijing Key Laboratory for Animal Models of Emerging and Reemerging Infectious Diseases,Institute of Laboratory Animal Science,Chinese Academy of Medical Sciences and Comparative Medicine Center,Peking Union Medical College,Beijing,China;State Key Laboratory of Respiratory Disease,National Clinical Research Center for Respiratory Disease,Guangzhou Institute of Respiratory Health,the First Affiliated Hospital of Guangzhou Medical University,Guangzhou,Guangdong,China;Institute of Infectious Disease,Guangzhou Eighth People's Hospital of Guangzhou Medical University,Guangzhou,Guangdong,China;Guangzhou Laboratory,Bio-Island,Guangzhou,China;Graduate School of Peking Union Medical College,No.9 Dongdan Santiao,Dongcheng District,Beijing,China;Division of HIV/AIDS and Sex-transmitted Virus Vaccines,Institute for Biological Product Control,National Institutes for Food and Drug Control(NIFDC),No.31 Huatuo Street,Daxing District,Beijing,China;Fulgent Pharma LLC.,4978 Santa Anita Avenue,Temple City,CA,USA
Lipid nanoparticle-encapsulated mRNA antibody provides long-term protection against SARS-CoV-2 in mice and hamsters
Yong-Qiang Deng;Na-Na Zhang;Yi-Fei Zhang;Xia Zhong;Sue Xu;Hong-Ying Qiu;Tie-Cheng Wang;Hui Zhao;Chao Zhou;Shu-Long Zu;Qi Chen;Tian-Shu Cao;Qing Ye;Hang Chi;Xiang-Hui Duan;Dan-Dan Lin;Xiao-Jing Zhang;Liang-Zhi Xie;Yu-Wei Gao;Bo Ying;Cheng-Feng Qin-State Key Laboratory of Pathogen and Biosecurity,Beijing Institute of Microbiology and Epidemiology,AMMS,Beijing,China;School of Medicine,Tsinghua University,Beijing,China;Kunming University of Science and Technology,Kunming,Yunnan,China;Suzhou Abogen Biosciences Co.,Ltd,Suzhou,Jiangsu,China;Key laboratory of Jilin Province for Zoonosis Prevention and Control,Changchun,Jilin,China;Beijing Protein and Antibody R&D Engineering Center,Sinocelltech Ltd,Beijing,China
Rapid development of an updated mRNA vaccine against the SARS-CoV-2 Omicron variant
Na-Na Zhang;Rong-Rong Zhang;Yi-Fei Zhang;Kai Ji;Xiao-Chuan Xiong;Qian-Shan Qin;Peng Gao;Xi-Shan Lu;Hang-Yu Zhou;Hai-Feng Song;Bo Ying;Cheng-Feng Qin-Department of Virology,State Key Laboratory of Pathogen and Biosecurity,Beijing Institute of Microbiology and Epidemiology,Academy of Military Medical Sciences,Beijing,China;School of Medicine,Tsinghua University,Beijing,China;Kunming University of Science and Technology,Kunming,Yunnan,China;Suzhou Abogen Biosciences Co.,Ltd.,Suzhou,Jiangsu,China;School of Life Sciences,Fujian Agriculture and Forestry University,Fuzhou,Fujian,China;Institute of Systems Medicine,Chinese Academy of Medical Sciences&Peking Union Medical College,Beijing,China;Research Unit of Discovery and Tracing of Natural Focus Diseases,Chinese Academy of Medical Sciences,Beijing,China
Peptide-based pan-CoV fusion inhibitors maintain high potency against SARS-CoV-2 Omicron variant
Shuai Xia;Jasper Fuk-Woo Chan;Lijue Wang;Fanke Jiao;Kenn Ka-Heng Chik;Hin Chu;Qiaoshuai Lan;Wei Xu;Qian Wang;Chao Wang;Kwok-Yung Yuenuai;Lu Lu;Shibo Jiang-Key Laboratory of Medical Molecular Virology(MOE/NHC/CAMS),School of Basic Medical Sciences,Shanghai Frontiers Science Center of Pathogenic Microbes and Infection,Shanghai Institute of Infectious Disease and Biosecurity,Fudan University,Shanghai,China;State Key Laboratory of Emerging Infectious Diseases,Carol Yu Centre for Infection,Department of Microbiology,Li Ka Shing Faculty of Medicine,The University of Hong Kong,Pokfulam,Hong Kong,China;Department of Clinical Microbiology and Infection Control,The University of Hong Kong-Shenzhen Hospital,Shenzhen,Guangdong,China;Centre for Virology,Vaccinology and Therapeutics,Hong Kong Science and Technology Park,Hong Kong,China;State Key Laboratory of Toxicology and Medical Countermeasures,Beijing Institute of Pharmacoloay and Toxicoloay,Beijing,China
Structural insights into the SARS-CoV-2 Omicron RBD-ACE2 interaction
Jun Lan;Xinheng He;Yifei Ren;Ziyi Wang;Huan Zhou;Shilong Fan;Chenyou Zhu;Dongsheng Liu;Bin Shao;Tie-Yan Liu;Qisheng Wang;Linqi Zhang;Jiwan Ge;Tong Wang;Xinquan Wang-The Ministry of Education Key Laboratory of Protein Science,Beijing Advanced Innovation Center for Structural Biology,Beijing Frontier Research Center for Biological Structure,Collaborative Innovation Center for Biotherapy,School of Life Sciences,Tsinghua University,Beijing,China;Microsoft Research Asia,Beijing,China;Shanghai Synchrotron Radiation Facility,Shanghai Advanced Research Institute,Chinese Academy of Sciences,Shanghai,China;Department of Chemistry,Tsinghua University,Beijing,China;Center for Global Health and Infectious Diseases,Comprehensive AIDS Research Center,and Beijing Advanced Innovation Center for Structural Biology,School of Medicine,Tsinghua University,Beijing,China
Structural and biochemical mechanism for increased infectivity and immune evasion of Omicron BA.2 variant compared to BA.1 and their possible mouse origins
Youwei Xu;Canrong Wu;Xiaodan Cao;Chunyin Gu;Heng Liu;Mengting Jiang;Xiaoxi Wang;Qingning Yuan;Kai Wu;Jia Liu;Deyi Wang;Xianqing He;Xueping Wang;Su-Jun Deng;H.Eric Xu;Wanchao Yin-The CAS Key Laboratory of Receptor Research,Shanghai Institute of Materia Medica,Chinese Academy of Sciences,Shanghai,China;Shanghai Jemincare Pharmaceuticals Co.,Ltd.,Shanghai,China;School of Chinese Materia Medica,Nanjing University of Chinese Medicine,Nanjing,Jiangsu,China;The Shanghai Advanced Electron Microscope Center,Shanghai Institute of Materia Medica,Chinese Academy of Sciences,Shanghai,China;University of Chinese Academy of Sciences,Beijing,China;School of Life Science and Technology,ShanghaiTech University,Shanghai,China;Zhongshan Institute for Drug Discovery,Shanghai Institute of Materia Medica,Chinese Academy of Sciences,Guangdong,China
Selection and structural bases of potent broadly neutralizing antibodies from 3-dose vaccinees that are highly effective against diverse SARS-CoV-2 variants,including Omicron sublineages
Lei Wang;Wangjun Fu;Linlin Bao;Zijing Jia;Yuxia Zhang;Yunjiao Zhou;Wei Wu;Jianbo Wu;Qianqian Zhang;Yidan Gao;Kang Wang;Qiao Wang;Chuan Qin;Xiangxi Wang-CAS Key Laboratory of Infection and Immunity,National Laboratory of Macromolecules,Institute of Biophysics,Chinese Academy of Sciences,Beijing,China;University of Chinese Academy of Sciences,Beijing,China;Key Laboratory of Human Disease Comparative Medicine,Chinese Ministry of Health,Beijing Key Laboratory for Animal Models of Emerging and Remerging Infectious Diseases,Institute of Laboratory Animal Science,Chinese Academy of Medical Sciences and Comparative Medicine Center,Peking Union Medical College,Beijing,China;Changping Laboratory,Beijing,China;Key Laboratory of Medical Molecular Virology(MOE/NHC/CAMS),Shanghai Institute of Infectious Disease and Biosecurity,Shanghai Frontiers Science Center of Pathogenic Microbes and Infection,School of Basic Medical Sciences,Shanghai Medical College,Fudan University,Shanghai,China
Safety and superior immunogenicity of heterologous boosting with an RBD-based SARS-CoV-2 mRNA vaccine in Chinese adults
Xiaoqiang Liu;Yuhua Li;Zhongfang Wang;Shouchun Cao;Weijin Huang;Lin Yuan;Yi-Jiao Huang;Yan Zheng;Jingjing Chen;Bo Ying;Zuoyun Xiang;Jin Shi;Jincun Zhao;Zhen Huang;Cheng-Feng Qin-Yunnan Province Centre for Disease Control and Prevention,Kunming,Yunnan,China;National Institutes for Food and Drug Control,Beijing,China;Respiratory Medicine,Guangzhou Institute of Respiratory Health,Guangzhou,Guangdong,China;Walvax Biotechnology Co.,Ltd.,Kunming,Yunnan,China;State Key Laboratory of Pathogen and Biosecurity,Beijing Institute of Microbiology and Epidemiology,Academy of Military Medical Sciences,Beijing,China;Suzhou Abogen Biosciences Co.,Ltd,Suzhou,Jiangsu,China;Research Unit of Discovery and Tracing of Natural Focus Diseases,Chinese Academy of Medical Sciences,Beijing,China
Hetero-bivalent nanobodies provide broad-spectrum protection against SARS-CoV-2 variants of concern including Omicron
Huan Ma;Xinghai Zhang;Peiyi Zheng;Peter H.Dube;Weihong Zeng;Shaohong Chen;Qingyu Cheng;Yunru Yang;Yan Wu;Junhui Zhou;Xiaowen Hu;Yan Xiang;Huajun Zhang;Sandra Chiu;Tengchuan Jin-Department of Pulmonary and Critical Care Medicine,The First Affiliated Hospital of USTC,Division of Life Sciences and Medicine,University of Science and Technology of China,Hefei,Anhui,China;State Key Laboratory of Virology,Wuhan Institute of Virology,Center for Biosafety Mega-Science,Chinese Academy of Sciences,Wuhan,Hubei,China;Laboratory of Structural Immunology,CAS Key Laboratory of Innate Immunity and Chronic Disease,Hefei National Laboratory for Physical Sciences at Microscale,Division of Life Sciences and Medicine,University of Science and Technology of China,Hefei,Anhui,China;Department of Microbiology,Immunology and Molecular Genetics,University of Texas Health Science Center at San Antonio,San Antonio,TX,USA;University of Chinese Academy of Sciences,Beijing,China;Institute of Health and Medicine,Hefei Comprehensive National Science Center,Hefei,Anhui,China
A broadly neutralizing antibody against SARS-CoV-2 Omicron variant infection exhibiting a novel trimer dimer conformation in spike protein binding
Yingdan Wang;Wuqiang Zhan;Jiangyan Liu;Yanqun Wang;Xiang Zhang;Meng Zhang;Lin Han;Yunping Ma;Lu Lu;Yumei Wen;Zhenguo Chen;Jincun Zhao;Fan Wu;Lei Sun;Jinghe Huang-Key Laboratory of Medical Molecular Virology(MOE/NHC/CAMS)and Shanghai Institute of Infectious Disease and Biosecurity,Shanghai Fifth People's Hospital,Shanghai Public Health Clinical Center,Institutes of Biomedical Sciences,School of Basic Medical Sciences,Fudan University,Shanghai,China;Shanghai Immune Therapy Institute,Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital,Shanghai,China;State Key Laboratory of Respiratory Disease,National Clinical Research Center for Respiratory Disease,Guangzhou Institute of Respiratory Health,the First Affiliated Hospital of Guangzhou Medical University,Guangzhou,Guangdong,China;Institute of Infectious Disease,Guangzhou Eighth People's Hospital of Guangzhou Medical University,Guangzhou,Guangdong,China
Early assessment of the safety and immunogenicity of a third dose(booster)of COVID-19 immunization in Chinese adults
Yuntao Zhang;Yunkai Yang;Niu Qiao;Xuewei Wang;Ling Ding;Xiujuan Zhu;Yu Liang;Zibo Han;Feng Liu;Xinxin Zhang;Xiaoming Yang-China National Biotec Group Company Limited,Beijing 100024,China;Shanghai Institute of Hematology,State Key Laboratory of Medical Genomics,National Research Center for Translational Medicine at Shanghai,Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine,Shanghai 200025,China;Beijing Institute of Biological Products,China National Biotec Group Company Limited,Beijing 100176,China;National Vaccine and Serum Institute,China National Biotec Group Company Limited,Beijing 101111,China;Department of Infectious Diseases,Research Laboratory of Clinical Virology,Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine,Shanghai 200025,China
机标中图分类号,由域田数据科技根据网络公开资料自动分析生成,仅供学习研究参考。